This is an old revision of this page, as edited by 86.30.243.179 (talk) at 16:20, 20 November 2011 (added original patent). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 16:20, 20 November 2011 by 86.30.243.179 (talk) (added original patent)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compoundClinical data | |
---|---|
ATC code |
|
Identifiers | |
IUPAC name
| |
CAS Number | |
PubChem CID | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H11F3N2O |
Molar mass | 304.267 g·mol |
3D model (JSmol) | |
SMILES
| |
(verify) |
Ro5-2904 (Triflunordazepam) is a drug which is a benzodiazepine derivative with high GABAA receptor affinity, and has anticonvulsant effects.
See also
References
- DE Patent 1136709
- Archives Internationales de Pharmacodynamie et de Therapie. (1965). Vol 154, p 131.
- So SS, Karplus M (1996). "Genetic neural networks for quantitative structure-activity relationships: improvements and application of benzodiazepine affinity for benzodiazepine/GABAA receptors". Journal of Medicinal Chemistry. 39 (26): 5246–56. doi:10.1021/jm960536o. PMID 8978853.
{{cite journal}}
: Unknown parameter|month=
ignored (help)
This sedative-related article is a stub. You can help Misplaced Pages by expanding it. |